Psoriasis Statistics

Psoriasis Statistics, Quality of Life, Age of Onset, Severity, and Cost: Essential Insights

By --
Saturday, 08 Jul, 2023

Psoriasis Statistics:

- In the U.S., over 8 million people are affected by psoriasis, and globally, around 125 million people (2-3% of the world's population) have the condition.

- About 30% of individuals with psoriasis also develop psoriatic arthritis.

- Psoriasis is less prevalent among African Americans (1.5%) compared to Caucasians (3.6%), but it may be underdiagnosed in people with skin of color.

Quality of Life:

- Nearly 60% of people with psoriasis experience significant impacts on their daily lives.

- Approximately 40% of individuals with psoriatic arthritis consider their disease a major problem in their everyday life.

- Women and younger patients, especially those with moderate to severe psoriasis, are more negatively affected in terms of their quality of life.

- Psoriasis is associated with higher rates of comorbidities, including

cardiovascular disease,
heart attack,
stroke,
metabolic syndrome, and
depression.

Age of Onset:

- Psoriasis can appear at any age, but it commonly manifests between 20-30 years and 50-60 years.

- Psoriatic arthritis usually develops between the ages of 30 and 50, but it can occur at any age.

Severity:

- Mild psoriasis affects less than 3% of the body, moderate psoriasis affects 3-10%, and severe psoriasis affects more than 10%.

- However, the severity of psoriasis is also determined by its impact on a person's quality of life. Around 25% of psoriasis cases are considered moderate to severe.

Cost:

- Patients with psoriasis incur significantly higher annual healthcare costs compared to the general population, totaling approximately $135 billion annually in the United States (as of 2013).

- Psoriasis places a substantial economic burden due to its

adverse physical,
psychiatric, and s
ocial consequences in the United States.

References-

[1] Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis Prevalence in Adults in the United States. JAMA Dermatol. Published online June 30, 2021. doi:10.1001/jamadermatol.2021.2007

[2] Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. Journal of the American Academy of Dermatology. 2013;69(5):729-735.

[3] Alexis AF, Blackcloud P. Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances. J Clin Aesthet Dermatol. 2014;7(11):16-24.

[4] Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2):136-139.

[5] Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. Journal of the American Academy of Dermatology. 2005;53(4):573.

[6] Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. Journal of the American Academy of Dermatology. 2004;51(5):704-708.

[7] Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of Myocardial Infarction in Patients With Psoriasis. JAMA. 2006;296(14):1735-1741.

[8] Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. The Journal of investigative dermatology. 2009;129(10):2411-2418.

[9] Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. Journal of the American Academy of Dermatology. 2013;68(4):654-662.

[10] Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. The Journal of investigative dermatology. 2014;134(6):1542-1551.

[11] Armstrong AW. Psoriasis. JAMA dermatology. 2017;153(9):956-956.

[12] Helmick CG, Lee-Han H, Hirsch SC, Baird TL, Bartlett CL. Prevalence of psoriasis among adults in the U.S.: 2003-2006 and 2009-2010 National Health and Nutrition Examination Surveys. American journal of preventive medicine. 2014;47(1):37-45.

[13] Brezinski EA, Dhillon JS, Armstrong AW. Economic Burden of Psoriasis in the United States: A Systematic Review. JAMA dermatology. 2015;151(6):651-658.

[14] Mercy K, Kwasny M, Cordoro KM, et al. Clinical manifestations of pediatric psoriasis: results of a multicenter study in the United States. Pediatric dermatology. 2013;30(4):424-428.

[15] Burden-Teh E, Thomas KS, Ratib S, Grindlay D, Adaji E, Murphy R. The epidemiology of childhood psoriasis: a scoping review. The British journal of dermatology. 2016;174(6):1242-1257.